The research conducted in our Unit lead to the generation of a new patent (Cardona, Vilaplana & Marzo, PCT/ES2013/000145) and the creation of a spin-off, Manremyc. The company is a spin-off of the Germans Trias i Pujol Foundation and the CIBER Enfermedades Respiratorias (from the ISCIII), with the aim to develop the revolutionary natural product designed to modulate the immune response against TB: the Nyaditum resae®. Dr Pere-Joan Cardona is the CEO/CSO of this company.
Since now, Manremyc has already built a solid and accurate preclinical dossier and conducted a Clinical Trial (ClinicalTrials.gov Identifier: NCT02076139) to demonstrate the tolerability of the nutraceutical, which results will be disseminated in the 45th Union World Conference on Lung Health.
This summer, Manremyc has raised 300,000€ in its 2nd capital round, an amount that will permit the search of international partners (basically in the Asia market and especially in India) to start selling Nyaditum resae® next year.
You can access the details of this new here: